Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

Fig. 5

SLC7A5 and breast cancer patient outcome. a SLC7A5 vs breast-cancer-specific survival (BCSS) in all discovery set cases. b SLC7A5 vs BCSS in all validation set cases. c SLC7A5 vs BCSS in oestrogen receptor (ER) + low proliferation tumours in the combined discovery and validation cases. d SLC7A5 vs BCSS in ER + high proliferation tumours in the combined discovery and validation cases. e SLC7A5 vs BCSS of triple negative tumours in the combined discovery and validation cases. f SLC7A5 vs BCSS human epidermal growth factor receptor 2 (HER2)+ tumours in the combined discovery and validation cases

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us